L.H. Pastushkova1, A.G. Goncharova2, M.I. Koloteva3, I.N. Goncharov4, N.G. Pilyaeva5, D.N. Kashirina6, I.M. Larina7

1–7 State Scientific Center of the Russian Federation – Institute of Biomedical Problems of the Russian Academy of Sciences (Moscow, Russia)

5 ZAO “BIOCHEMMAK” (Moscow, Russia)

It is promising to use a short-range centrifuge as a measure to prevent changes in the physiological systems of the body under the influence of microgravity.

The aim of the work was to determine the level of ST2 in relation to the risk of developing cardiovascular changes after a single rotation on a short-radius centrifuge. The level of cardiomarker ST2 was assessed after a single exposure to a short-radius centrifuge with the participation of 6 apparently healthy male volunteers 39 ± 6 years old. The operating factor in the tests was the overload direction "head - pelvis" (+Gz). The total rotation time was 60 minutes. The sST2 level was assessed by enzyme-linked immunosorbent assay (ELISA).

It was established that a single rotation on the CCR did not cause a significant increase in the level of ST2. The data obtained indicate the absence of biochemical signs of pathological hyperextension or myocardial damage in this regimen of CCR.

The relative decrease in the level of ST2 may indirectly indicate the possibility of using a single exposure to CCR in this mode to prevent changes induced by microgravity.

Pastushkova L.H., Goncharova A.G., Koloteva M.I., Goncharov I.N., Pilyaeva N.G., Kashirina D.N., Larina I.M. Estimation of the level of cardiomarker ST2 during a single exposure to a short-radius centrifuge. Biomedicine Radioengineering. 2023. V. 26. № 1.
Р. 54-59. DOI: https://doi.org/10.18127/j15604136-202301-06 (In Russian).

1. Orlov O.I., Koloteva M.I. Tsentrifuga korotkogo radiusa kak novoye sredstvo profilaktiki neblagopriyatnykh effektov nevesomosti i perspektivnyye plany po razrabotke problemy iskusstvennoy sily tyazhesti primenitelno k mezhplanetnym poletam. Aviakosmicheskaya i ekologicheskaya meditsina. 2017. T. 51. № 7. DOI: 10.21687/0233-528X-2017-51-7.11-18 (in Russian).
2. Uchasova E.G., Gruzdeva O.V., Dyleva Yu.A., Karetnikova V.N. Interleykin-33 i fibroz: sovremennyy vzglyad na patogenez. Meditsinskaya immunologiya. 2018. T. 20. № 4. S. 477–484. (in Russian).
3. Januzzi J.L.Jr. ST2 as a cardiovascular risk biomarker: from the bench to the bedside. J. Cardiovasc. Transl. Res. 2013. V. 6(4). P. 493–500. DOI: 10.1007/s12265-013-9459-y
4. Jirak P., Wernly B., Lichtenauer M., Paar V., Franz M., Knost T., Abusamrah T., Kelm M., Muessig J.M., Bimpong-Buta N.Y., Jung C. Dynamic Changes of Heart Failure Biomarkers in Response to Parabolic Flight. Int. J. Mol. Sci. 2020. V. 21(10). P. 3467. DOI: 10.3390/ijms21103467
5. Mahmood S.S., Levy D., Vasan R.S., Wang T.J. The Framingham Heart Study and the epidemiology of cardiovascular disease: a historical perspective. Lancet. 2014. V. 383. № 9921. P. 999–1008. DOI: 10.1016/S0140-6736(13)61752-3
6. Gruson D., Lepoutre T., Ahn S.A., Rousseau M.F. Increased soluble ST2 is a stronger predictor of long-term cardiovascular death than natriuretic peptides in heart failure patients with reduced ejection fraction. Int. J. Cardiol. 2014. V. 172. № 1. e250–2. doi: 10.1016/j.ijcard.2013.12.101
7. Bimpong-Buta N.Y., Jirak P., Wernly B., Lichtenauer M., Knost T., Abusamrah T., Kelm M., Jung C. Blood parameter analysis after short term exposure to weightlessness in parabolic flight. Clin. Hemorheol. Microcirc. 2018. V. 70. P. 477–486.
8. Goncharova A.G., Pastushkova L.Kh., Kireyev K.S., Kashirina D.N., Goncharov I.N., Koloteva M.I., Pilyayeva N.G., Larina I.M. Vliyaniye faktorov dlitelnykh kosmicheskikh poletov i prizemleniya na urovni biomarkera serdechnoy nedostatochnosti i riska razvitiya fibroza ST2. Pilotiruyemyye polety v kosmos. 2023. № 1. S. 3–7. (in Russian).
9. Kamardinov D.Kh., Songurov R.N., Ioshina V.I., Buziashvili Yu.I. Rastvorimyy ST2 – kak biomarker. instrument stratifikatsii riska i terapevticheskaya mishen u patsiyentov s khronicheskoy serdechnoy nedostatochnostyu. Kardiologiya. 2020. T. 60. № 2. S. 111–121. (in Russian).
10. Azakie A., Fineman J.R., He Y. Sp3 inhibits Sp1-mediated activation of the cardiac troponin T promoter and is downregulated during pathological cardiac hypertrophy in vivo. Am. J. Physiol. Circ. Physiol. 2006. V. 291. H600–H611.
11. Lupón J., Gaggin H.K., de Antonio M., Domingo M., Galán A., Zamora E., Vila J., Peñafiel J., Urrutia A., Ferrer E., Vallejo N., Januzzi J.L., Bayes-Genis A. Biomarker-assist score for reverse remodeling prediction in heart failure: The ST2-R2 score. Int. J. Cardiol. 2015. V. 184. P. 337–343. DOI: 10.1016/j.ijcard.2015.02.019
12. Ojji D.B., Opie L.H., Lecour S., Lacerda L., Adeyemi O., Sliwa K. Relationship between left ventricular geometry and soluble ST2 in a cohort of hypertensive patients. J. Clin. Hypertens. (Greenwich). 2013. V. 15(12). P. 899–904. DOI: 10.1111/jch.12205
13. Dudek M., Kałużna-Oleksy M., Migaj J., Straburzyńska-Migaj E. Clinical value of soluble ST2 in cardiology. Adv. Clin. Exp. Med. 2020. V. 29(10). P. 1205–1210. DOI: 10.17219/acem/126049
14. Molodtsov V.O., Smirnov V.Yu., Solnushkin S.D., Chikhman V.N. Apparatno-programmnoye obespecheniye povedencheskogo eksperimenta. Biomeditsinskaya radioelektronnika. 2021. T. 24. № 1. S. 42–47. (in Russian).